Pharmaceutical

Jamieson Wellness Inc. ("Jamieson Wellness" or the "Company") (TSX:JWEL) announced today that the Company will release its first quarter 2021 financial results after the market close on Wednesday, May 5, 2021. The Company will host a conference call for investors at 5:00 p.m. Eastern Time to discuss the first quarter 2021 results.

The call can be accessed live over the telephone by dialing 1-866-248-8441 from Canada and the U.S. or 1-323-289-6576 from international locations. A replay will be available shortly after the call and can be accessed by dialing 1-844-512-2921 from Canada and the U.S. or 1-412-317-6671 from international locations. The passcode for the replay is 6067552 and it will be available until Wednesday, May 19, 2021.

Interested parties may listen to a simultaneous webcast of the conference call by logging on via the Investor Relations section of the Company's website at https://www.jamiesonwellness.com/English/investors/home/default.aspx or directly at http://public.viavid.com/player/index.php?id=144443 . A replay of the webcast will be available for approximately 30 days following the call.

About Jamieson Wellness Inc.

Jamieson Wellness is dedicated to improving the world's health and wellness with its portfolio of innovative natural health brands. Established in 1922, Jamieson is the Company's heritage brand and Canada's #1 consumer health brand. Jamieson Wellness manufactures and markets sports nutrition products and specialty supplements under its Progressive, Precision and Iron Vegan brands. The Company also markets Smart Solutions, the #1 women's natural health focused brand in Canada. For more information please visit jamiesonwellness.com.

Investor and Media Contact:
Ruth Winker
Jamieson Wellness
416-705-5437
rwinker@jamiesonlabs.com

News Provided by Business Wire via QuoteMedia

Love Pharma Announces Closing of MicroDoz Therapy Acquisition

Love Pharma Announces Closing of MicroDoz Therapy Acquisition

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

Love Pharma Co. ("LOVE" and or "The Company") (CSE:LUV)(FSE:G1Q0), is pleased to announce that it has completed its acquisition (the "Acquisition") of MicroDoz Theraphy Inc. ("MicroDoz") (as originally disclosed in a press release on November 23, 2021 and as updated on March 3, 2022

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

Astellas Highlights Data on Advanced and Rare Cancers during 2022 ASCO Annual Meeting and EHA 2022 Hybrid Congress

Abstracts represent exciting research progress across four cancers where patients have limited treatment options

Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa Ph.D., "Astellas") will share new research during the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting from June 3-7 and the European Hematology Association (EHA) 2022 Hybrid Congress from June 9-12 . A total of 13 abstracts from the company's expanding portfolio of approved and investigational therapies will be presented across both meetings, underscoring the company's commitment to advancing treatment options for advanced and rare cancers, including prostate, pancreatic and urothelial cancer, as well as acute myeloid leukemia (AML).

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Biohaven Pharmaceutical Holding Co. Ltd. Buyout

Rigrodsky Law, P.A. is investigating Biohaven Pharmaceutical Holding Co. Ltd. ("Biohaven") (NYSE: BHVN) regarding possible breaches of fiduciary duties and other violations of law related to Biohaven's agreement to be acquired by Pfizer Inc. (NYSE: PFE). Under the terms of the agreement, Biohaven's shareholders will receive $148.50 in cash for each share of Biohaven common stock they own.

To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-biohaven-pharmaceutical-holding-co-ltd.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

BIOHAVEN INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Biohaven Pharmaceutical Holding Company Ltd. - BHVN

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) to Pfizer Inc. (NYSE: PFE).  Under the terms of the proposed transaction, shareholders of Biohaven will receive only $148.50 in cash and 0.5 of a share of New Biohaven, a new publicly traded company that will retain Biohaven's non-CGRP development stage pipeline compounds, for each share of Biohaven that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.

KSF Filing Alert (PRNewsfoto/Kahn Swick & Foti, LLC)

If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ( lewis.kahn@ksfcounsel.com ) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nyse-bhvn/ to learn more.

To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com .

Kahn Swick & Foti, LLC
1100 Poydras St., Suite 3200
New Orleans, LA 70163

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/biohaven-investor-alert-by-the-former-attorney-general-of-louisiana-kahn-swick--foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-biohaven-pharmaceutical-holding-company-ltd---bhvn-301544504.html

SOURCE Kahn Swick & Foti, LLC

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

SHAREHOLDER ALERT: Weiss Law Investigates Biohaven Pharmaceutical Holding Company Ltd.

Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Biohaven Pharmaceutical Holding Company Ltd. ("Biohaven" or the "Company") (NYSE: BHVN) in connection with the proposed acquisition of the Company by Pfizer Inc. ("Pfizer") (NYSE: PFE). Under the terms of the merger agreement, Pfizer will acquire all outstanding shares of Biohaven not already owned by Pfizer for $148.50 per share in cash. Biohaven common shareholders, including Pfizer, will also receive 0.5 of a share of New Biohaven per Biohaven common share, a new publicly traded company that will retain Biohaven's non-calcitonin gene-related peptide development stage pipeline compounds.

(PRNewsfoto/WeissLaw LLP)

If you own Biohaven shares and wish to discuss this investigation or have any questions concerning this notice or your rights or interests, visit our website:
https://www.weisslaw.co/news-and-cases/bhvn
Or please contact:
Joshua Rubin, Esq.
Weiss Law
305 Broadway, 7 th Floor
New York , NY  10007
(212) 682-3025
(888) 593-4771
stockinfo@weisslawllp.com

Weiss Law is investigating whether (i) Biohaven's board of directors acted in the best interests of Company shareholders in agreeing to the proposed transaction, (ii) the per-share merger consideration adequately compensates Biohaven's shareholders, and (iii) all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed.

Weiss Law has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties.  We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases.  If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at stockinfo@weisslawllp.com

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/shareholder-alert-weiss-law-investigates-biohaven-pharmaceutical-holding-company-ltd-301544263.html

SOURCE Weiss Law

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

BIOHAVEN ALERT: Bragar Eagel & Squire, P.C. Investigates Merger of BHVN and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) breached their fiduciary duties or violated the federal securities laws in connection with the company's acquisition by Pfizer, Inc. (NYSE: PFE).

Click here to learn more and participate in the action.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×